预约演示
更新于：2026-05-19
Delamanid
德拉马尼
更新于：2026-05-19
概要
基本信息
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 欧盟 (2014-04-27), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国)、孤儿药 (日本)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
分子式C25H25F3N4O6 |
InChIKeyXDAOLTSRNUSPPH-XMMPIXPASA-N |
CAS号681492-22-8 |
关联
44
项与 德拉马尼 相关的临床试验NCT07198685
6 Months of Bedaquiline, Delamanid, Linezolid and Levoffoxacin in RR-TB Patients in Hubei Province
This study aims to compare the efficacy and safety of a 6-month all-oral regimen including Bedaquiline (BDQ,B), Delamanid (DLM,D), Linezolid (LZD, L), and Levofloxacin (LFX,L) to the the standard long - course treatment regimen within the Chinese population. The main questions it aims to answer are:
Is the efficacy of short regimen non-inferior to standard regimen? Is the short regimen safe enough to replace the standard regimen?
Participants will:
Be given with either short or standard regimen for RR-TB treatment Be asked to complete the scheduled visit as planned.
Is the efficacy of short regimen non-inferior to standard regimen? Is the short regimen safe enough to replace the standard regimen?
Participants will:
Be given with either short or standard regimen for RR-TB treatment Be asked to complete the scheduled visit as planned.
开始日期2025-09-30 |
申办/合作机构- |
ChiCTR2500108732
A Multicenter, Open-label, Randomized, Active-controlled Clinical Study to Compare the Efficacy and Safety of Different Combination Regimens of JDB0131 Benzenesulfonate Tablets with Delamanid in Patients with Rifampin-resistant Tuberculosis (JD-RISE)
开始日期2025-09-10 |
申办/合作机构 首都医科大学附属北京胸科医院 [+2] |
NCT07129629
Short-Course Regimen With Bedaquiline, Moxifloxacin and Pyrazinamide for Early Bactericidal Activity in Drug-Susceptible Tuberculosis
# Brief Summary
This study aims to evaluate the early bactericidal activity (EBA), safety, and tolerability of 4-month short-course regimens containing bedaquiline, moxifloxacin, and pyrazinamide in patients with drug-susceptible tuberculosis. This is a prospective, randomized, controlled, multicenter study planned to enroll 45 rifampicin-susceptible tuberculosis patients, who will be randomized in a 1:1:1 ratio to the BZMD group (bedaquiline + pyrazinamide + moxifloxacin + delamanid), BZMH group (bedaquiline + pyrazinamide + moxifloxacin + isoniazid), and standard control group. Subjects in the test groups will receive 17 weeks (4 months) of group-specific treatment regimens, while subjects in the control group will receive 26 weeks (6 months) of standard HRZE regimen treatment.
The primary endpoint is the change from baseline in log₁₀ colony-forming units (CFU) per milliliter of sputum specimen from Day 0 (pre-dose) to Day 14 of treatment (EBA CFU₀-₁₄), used to evaluate the early bactericidal activity of the drugs. Secondary endpoints include EBA CFU and EBA TTP (time to positive culture) at other time intervals, pharmacokinetic characteristics, sustained microbiological clearance rates, relapse rates, and safety indicators. The study will analyze the daily decline in log₁₀ CFU counts and daily increase in TTP using nonlinear mixed-effects models to reflect the bactericidal activity of the study regimens.
This study will help provide more effective and safer short-course treatment options for Chinese patients with drug-susceptible tuberculosis, thereby improving treatment adherence and treatment success rates, and providing scientific evidence for optimizing short-course treatment regimens for drug-susceptible tuberculosis.
This study aims to evaluate the early bactericidal activity (EBA), safety, and tolerability of 4-month short-course regimens containing bedaquiline, moxifloxacin, and pyrazinamide in patients with drug-susceptible tuberculosis. This is a prospective, randomized, controlled, multicenter study planned to enroll 45 rifampicin-susceptible tuberculosis patients, who will be randomized in a 1:1:1 ratio to the BZMD group (bedaquiline + pyrazinamide + moxifloxacin + delamanid), BZMH group (bedaquiline + pyrazinamide + moxifloxacin + isoniazid), and standard control group. Subjects in the test groups will receive 17 weeks (4 months) of group-specific treatment regimens, while subjects in the control group will receive 26 weeks (6 months) of standard HRZE regimen treatment.
The primary endpoint is the change from baseline in log₁₀ colony-forming units (CFU) per milliliter of sputum specimen from Day 0 (pre-dose) to Day 14 of treatment (EBA CFU₀-₁₄), used to evaluate the early bactericidal activity of the drugs. Secondary endpoints include EBA CFU and EBA TTP (time to positive culture) at other time intervals, pharmacokinetic characteristics, sustained microbiological clearance rates, relapse rates, and safety indicators. The study will analyze the daily decline in log₁₀ CFU counts and daily increase in TTP using nonlinear mixed-effects models to reflect the bactericidal activity of the study regimens.
This study will help provide more effective and safer short-course treatment options for Chinese patients with drug-susceptible tuberculosis, thereby improving treatment adherence and treatment success rates, and providing scientific evidence for optimizing short-course treatment regimens for drug-susceptible tuberculosis.
开始日期2025-08-20 |
申办/合作机构 上海市肺科医院 [+2] |
100 项与 德拉马尼 相关的临床结果
登录后查看更多信息
100 项与 德拉马尼 相关的转化医学
登录后查看更多信息
100 项与 德拉马尼 相关的专利（医药）
登录后查看更多信息
997
项与 德拉马尼 相关的文献（医药）2026-07-01·JOURNAL OF MOLECULAR GRAPHICS & MODELLING
Elucidating the structural basis of Fgd1-mediated resistance to Delamanid in Mycobacterium tuberculosis
Article
作者: Guruprasad, Lalitha ; Saxena, Shalini
Delamanid and Pretomanid are nitro-dihydro-imidazooxazole derivatives essential for the treatment of multidrug-resistant tuberculosis (MDR-TB). The emergence of tuberculosis resistance to Delamanid necessitates understanding the molecular mechanisms underlying this resistance. This study focuses on the structural analysis of the fgd1 protein in both wild-type and mutant forms to explain the molecular basis of Delamanid resistance. Since the fgd1 complex with the F420 cofactor is responsible for the activation of Delamanid, we investigated the impact of mutations on the structural stability, primarily using molecular dynamics simulations, and electronic properties using quantum mechanics/molecular mechanics (QM/MM) studies of the fgd1-F420 complex. Among the pool of available mutants, we selected 12 fgd1 mutants (K9A, L70R, G71D, Q88E, M93R, N112K, A176D, G191D, K198A, E230K, W284S, and G314E) that exhibited resistance to Delamanid. A significant change in the protein and cofactor conformation was observed in some mutants compared to that in the wild-type, with increased RMSD and RMSF. To further analyze the binding affinity between fgd1-F420 WT and the mutants in detail, we performed MM-GBSA calculations and observed reduced F420 binding for K9A, G71D, N112K, K198A, and W284S mutations. Additionally, QM/MM calculations demonstrated how mutations influenced the electronic environment of fgd1, indicating that all mutations, except K9A, led to reduced stability. These alterations suggest that mutations may alter the local electronic environment, potentially affecting the cofactor binding and catalytic processes. Overall, these results provide new structural insights and vital clues for designing novel inhibitors to combat nitroimidazole resistance.
2026-06-01·Public health in practice (Oxford, England)
A scoping review of interventions in childhood tuberculosis prevention and treatment
Review
作者: Nahrin, Ridwana ; Shahrin, Lubaba ; Bushra, Israt Jahan ; Rahaman, Md Zamiur ; Banu, Sayera ; Ahmed, Shahriar ; Alam, Tahmina ; Nahar, Syeda Shamsun
Objective:
This scoping review aims to identify and map the available evidence on interventions for the prevention and treatment of childhood TB, confirm current practice, explore variation, and identify emerging approaches.
Study design:
Scoping review.
Method:
This scoping review was conducted using established methods and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) checklist. The protocol was registered with the Open Science Framework. Selection criteria were defined using the PCC framework, including population (children aged 0-18 years), concept (prevention and treatment of tuberculosis), and context (global settings). Studies with control groups were included, such as randomised controlled trials (RCTs), quasi-experimental studies, cohort studies, case-control studies, and cross-sectional studies. Electronic databases (PubMed, Web of Science, Scopus, Cochrane Library, and EMBASE) and websites of global health agencies (e.g., USAID, UNICEF, WHO, and CDC) were searched.
Results:
Following a comprehensive search and screening process, 41 studies were included. Of these, 15 were conducted in the African region (with South Africa contributing the most, n = 7), followed by Southeast Asia (n = 12), Europe (n = 6), the Western Pacific (n = 4), the Eastern Mediterranean (Pakistan, n = 2), the Americas (USA, n = 1), and one multi-country study. Eighteen studies focused on TB prevention, 22 on treatment, and one on both. The review found that combining pharmaceutical and non-pharmaceutical interventions improved prevention outcomes, with treatment completion rates reaching up to 99% and reductions in mortality. The BCG vaccine showed variable efficacy (22-92%), with over 70% protection against TB meningitis reported in several regions. Treatment success rates for drug-sensitive TB reached up to 97%. New regimens incorporating bedaquiline and delamanid for multidrug-resistant (MDR-TB) and extensively drug-resistant TB (XDR-TB) showed cure rates as high as 94.6%.
Conclusion:
Overall, shorter treatment regimens were associated with higher completion rates, although evidence on long-term cure remains limited.
2026-06-01·INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Spontaneous mutations to delamanid and pretomanid resistance in Mycobacterium tuberculosis: SNPs confer high-level resistance
Article
作者: Pi, Rui ; Xu, Peng ; Zhang, Qian ; Chen, Yiwang ; Gao, Qian ; Zhang, Xuecong ; Takiff, Howard
OBJECTIVES:
Multidrug-resistant tuberculosis (MDR-TB) remains a major global health threat. Delamanid (DLM) and pretomanid (PMD) are core drugs in new multidrug-resistant tuberculosis regimens, but the spectrum of their resistance mutations is poorly defined.
METHODS:
To investigate these mutations, five parallel in vitro experiments selected for resistance to DLM or PMD. Mycobacterium tuberculosis H37Rv cultures were plated on twice the critical concentrations (CC) of DLM (0.4 µg/mL) or PMD (4 µg/mL) to select resistant clones. Minimum inhibitory concentration (MIC) testing quantified the level of resistance and whole-genome sequencing (WGS) of pooled and individual clones identified mutations associated with drug resistance.
RESULTS:
Each parallel experiment yielded about 150 DLM-resistant and 200 PMD-resistant colonies. Pooled-colony WGS detected 102 mutations across six resistance-associated genes (ddn, fgd1, fbiA, fbiB, fbiC, fbiD). MIC assays of 259 individual colonies showed extensive DLM-PMD cross-resistance, with most isolates exhibiting high-level resistance (MIC ≥32 × CC, ≥6.4 µg/mL for DLM and ≥64 µg/mL for PMD) to both drugs. WGS of 100 randomly selected single colonies revealed that non-synonymous single-nucleotide polymorphisms (SNPs), loss-of-function (LoF) mutations, and inframe indels all confer high-level resistance. Of the 111 mutations identified, only six were reported in previous in vitro selection studies. According to the WHO mutation catalogue, 14 loss-of-function mutations were identified as resistant mutations.
CONCLUSION:
In conclusion, in vitro selection demonstrated a high diversity of resistance mutations. Most mutations, including single-nucleotide polymorphisms, confer resistance to both DLM and PMD.
51
项与 德拉马尼 相关的新闻（医药）2026-05-17
结核病（TB）至今仍是全球范围内由单一感染性病原体导致死亡的主要原因之一。根据WHO数据，2022年全球约有1060万人罹患结核病，约130万人因此死亡。长期以来，药物敏感结核病（DS-TB）的标准治疗周期为6至9个月，相较其他感染性疾病显著偏长。漫长的疗程不仅增加了患者依从性管理的难度，也加大了治疗失败和耐药结核分枝杆菌（Mtb）出现的风险。因此，缩短结核病治疗疗程已成为当前结核病药物研发的核心目标之一。本文基于Vinayak Singh发表于《Drug Discovery Today》（2024年5月）的综述，对这一领域的现状与前景做一梳理，供临床同道参考。
一、为什么我们需要缩短结核病疗程？
从公共卫生、临床和社会经济三个层面来看，缩短结核病疗程的意义都非常突出。
在公共卫生层面，较长的疗程往往导致较高的患者失访率，治疗不完整又会进一步催生耐药。缩短疗程有助于提高治疗完成率，从而减少传播、改善公共卫生结局；同时，较短方案所需药物更少、医务人员投入更少，可显著降低医疗系统的成本；在疫情暴发情境下，短程方案也更易于快速部署，有助于控制疾病扩散。
在临床层面，长疗程与复发风险、耐药突变及多种药物相关不良反应密切相关。新一代、更有效的药物若能用于短程方案，有望提升治疗效果、降低复发率，同时减少耐药发生的时间窗口，并改善患者耐受性。
在社会经济层面，较长的治疗会影响患者的工作与生活，并在部分社区中带来污名化困扰，对边缘化人群（如无家可归者、难民、药物使用者）尤其不利。短程方案有助于患者更快回归社会、减少病耻感，并改善这些人群获得规范治疗的可及性。
二、目前在DS-TB和耐药结核病疗程缩短方面的进展
从1952年的24个月标准疗程，到2022年的4个月方案，DS-TB治疗疗程的缩短虽缓慢但持续推进。
DS-TB方面：多中心、随机、开放标签的III期非劣效性试验Study 31/A5349，验证了以利福喷丁和莫西沙星为基础（联合异烟肼和吡嗪酰胺）的4个月方案非劣效于标准6个月方案，WHO已于2022年予以认可。
MDR-TB和RR-TB方面：在FDA批准后，WHO目前推荐6个月的BPaL方案（贝达喹啉-普托马尼-利奈唑胺），或加用莫西沙星形成BPaLM方案，用于特定形式的MDR-TB和利福平耐药结核病。相比此前约18个月的MDR-TB治疗疗程，这是一次显著缩短。
更短疗程的探索：TRUNCATE-TB试验显示，以贝达喹啉-利奈唑胺为基础的8周口服方案，在临床结局上非劣效于标准治疗。但需要注意的是，相关后续评论指出：大多数接受标准方案治疗的患者在4个月时即不再复发；并且基于贝达喹啉的更短疗程可能因其较长的终末半衰期而在治疗结束后数月内维持亚治疗浓度，这种长时间的亚致死浓度"单药暴露"可能促发耐药，该试验中已观察到两例获得性耐药病例。
此外，一项基于BALB/c小鼠模型的研究提示，BPaL方案仍有进一步优化空间——研究者尝试以新型二芳基喹啉类药物TBAJ-587或TBAJ-876替代贝达喹啉，并以更安全的新型噁唑烷酮TBI-223替代利奈唑胺，相关组合仍处于研究阶段，临床价值有待进一步验证。
三、新药、新方案与先进研究工具的作用
正在推进的临床联合方案研究包括：
· PRESCIENT试验（IIc期）：比较12周BCZD方案（贝达喹啉、氯法齐明、吡嗪酰胺、德拉马尼）与标准方案治疗DS-TB的疗效与安全性。（NCT05556746，尚未公布）
· DECODE试验（IIb期）：评估Delpazolid（DZD）联合贝达喹啉-德拉马尼-莫西沙星（BDM）方案的剂量-效应关系。（NCT04550832；https://pubmed.ncbi.nlm.nih.gov/40645198/）
· mBPaL试验：在Nix-TB和ZeNix基础上调整利奈唑胺剂量，旨在为耐药结核病确定更优的利奈唑胺给药策略。（https://pubmed.ncbi.nlm.nih.gov/39194339/）
· PredictTB试验（IIb期）：探索对病情较轻者使用4个月标准DS-TB方案是否非劣效于6个月方案，并尝试识别可用于预测疗程长度的免疫学生物标志物或转录组学特征。（https://pubmed.ncbi.nlm.nih.gov/39802795/）
新药研发管线正在持续扩展。当前处于临床开发阶段的候选药物覆盖多个研发阶段：I期候选药物包括TBAJ-587、TBI-223（已进入IIa）、GSK-286（因不良反应已被移除）和macozinone（PBTZ-169，已进入Phase 2）；II期候选药物包括telacebec（Q203）、alpibectir（BVL-GSK098）、BTZ-043、TBAJ-876、sanfetrinem、TBA-7371、quabodepistat（OPC-167832，已进入三期）、ganfeborole（GSK-3036656）、pyrifazimine（TBI-166）、SQ109、delpazolid、sutezolid和tedizolid；III期候选药物包括sudapyridine（WX-081）。此外，fobrepodacin（SPR720，Ia/Ib）、JSF-3285、CPZEN-45等多个来自新化学类别的候选物仍处于临床前研究阶段。这一管线提示，围绕缩短结核病治疗疗程的新药和新方案探索仍在积极推进，但多数候选物仍需进一步临床验证。
需要强调的是，贝达喹啉、德拉马尼、普托马尼这三种近年来获批的新药均已观察到耐药出现，提示对新靶点新药的探索必须持续推进。
先进研究工具方面，结核病肉芽肿在结构上呈纤维化、细胞性/非坏死性、干酪样/坏死性或空洞性等不同形态，Mtb在其中形成多样化的耐药耐受机制。为识别可对所有非复制态Mtb起效的药物，离体兔干酪样组织模型及由其优化而来的、基于裂解变性泡沫巨噬细胞的"干酪替代"中通量检测平台，正被用于评价药物的灭菌活性。DiaMOND方法可在不需要完整组合矩阵的前提下评估多药相互作用，有助于发现具有协同或增效作用的药物组合。PK/PD建模在利福喷丁优化给药剂量和Study 31方案设计中发挥了重要作用，未来在预测治疗结局、降低复发风险方面具有重要潜力。基于核糖体RNA合成比率联合菌落计数的多PD标志物方法，也为评估药物对耐药耐受细胞的作用提供了新思路。
四、诊断与依从性管理同样关键
正如原文所引用的观点："如果我们找不到结核病，就无法治疗结核病；如果不能治疗结核病，就不能终结结核病。"早期、准确的诊断是缩短疗程不可或缺的一环。
目前可用的先进诊断手段包括：WHO推荐作为肺结核首选检测的Xpert（MTB/RIF或MTB/RIF Ultra）和Truenat，以及用于评估耐药的线性探针检测（LPA，如Genotype MTBDRplus和MTBDRsl）；用于无法咳痰患者（尤其HIV感染者）的LF-LAM尿液检测；评估潜伏感染的IGRA血清生物标志物检测；用于菌株鉴定、传播追踪和耐药监测的全基因组测序（WGS）；以及基于人工智能的胸片自动判读软件CAD4TB。这些工具在敏感性、出报告速度、可及性和监测能力上各具优势。
治疗依从性方面，直接督导下治疗（DOT）在多数中低收入国家广泛应用，但目前缺乏强有力的证据证明其在治疗成功率上显著优于自我管理用药。提升依从性的可行策略包括：将DOT下沉至社区卫生中心或药店等更便利的地点；采用每周或每两周一次的督导方式或由患者自选督导员；提供经济和社会支持以减轻交通和误工负担；以及利用短信提醒、视频DOT等技术手段。此外，针对病耻感、结核病知识不足、药物不良反应等深层因素开展健康教育和心理咨询，并加强营养、医疗可及性和社区支持，同样至关重要。
五、当前面临的挑战与未来方向
尽管进展令人鼓舞，疗程缩短目标的实现仍面临多重挑战，包括：从庞大化合物库中筛选具有临床开发潜力候选物的难题；对治疗缩短组合进行排序所需的高资源投入；对联合方案中各药物个体贡献理解有限；缺乏可用于评价治疗反应的"替代标志物"；难以彻底清除休眠菌以避免复发；在疗效与安全性之间取得平衡；以及需要更严格监测以防止耐药出现等。
未来方向上，除了继续开发新药与优化方案外，还需关注干酪坏死性肉芽肿内部的微环境差异——例如氯法齐明在低氧条件下活性有限，吡嗪酰胺和贝达喹啉在肉芽肿内部因pH及病灶特异性药物分布而疗效受影响——这些都凸显了选用能准确模拟肺部病理的动物模型的重要性。宿主导向治疗（HDT）作为辅助手段是另一具有潜力的方向，二甲双胍、伊马替尼、普伐他汀、金诺芬等多项HDT临床研究正在进行中，仍需进一步验证其在提高治愈率、缩短疗程和减少残余组织损伤方面的临床价值。此外，在DS-TB标准方案中加入贝达喹啉或普托马尼能否预防或减少耐药菌株的重复感染、是否存在针对持留菌的有效方案，均有待研究。
结语
缩短结核病治疗疗程不仅能改善患者依从性，也有助于遏制耐药发生、减少传播。从1952年的24个月到2022年的4个月，进展虽缓但方向明确。要实现"<8周"的目标，仍需政府、药企、学界、监管机构等多方协同，加大在结核病药物研发上的投入。对临床医生而言，理解新方案的循证基础、把握新药与新工具的发展动态、并在日常诊疗中重视早诊断和依从性管理，将是参与并推动这一进程的重要方式。
本文内容基于原文综述整理，仅用于学术交流，不替代指南或个体化临床决策。
Singh V. Tuberculosis treatment-shortening[J]. Drug Discovery Today, 2024, 29(5): 103955.
更多资讯：
1. 结核病-治疗篇 2. 结核病-实验室诊断篇
3. 结核病-公共卫生篇 4. 结核病-基础研究篇
5. 结核病-NTM及其他 6. 科研门诊
备注：
本公众号发布的文章内容主要来源于互联网公开资料，经翻译、整理与归纳，仅供学习与学术交流使用。相关内容的版权归原作者及相关权利人所有。
如转载内容涉及版权或其他权益问题，请权利人及时与我们联系，我们将在核实后第一时间进行处理或删除。
欢迎关注、点赞并分享！也欢迎转发或转载（本文已开通快捷转载）。
2026-04-29
International Journal of Antimicrobial Agents Volume 67, Issue 5
国际抗微生物制剂杂志 67卷5期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/5
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与资讯页）
1.
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page
国际抗菌化疗学会（ISAC）新闻与资讯页
Article 107803
Global Landscape of Phage Therapy（噬菌体疗法的全球概况）
2.
Assessing carbonylation in Pseudomonas aeruginosa clinical isolates infected by bacteriophages using flow cytometry
利用流式细胞术评估受噬菌体感染的铜绿假单胞菌临床分离株中的羰基化情况
Jia Hao Yeo, Shuhua Thong, Shimin Jasmine Chung, Andrea Lay-Hoon Kwa
Article 107739
AI strategies to combat AMR（应对抗菌药物耐药性的人工智能策略）
3.
Causality-informed models for multidrug-resistant organism prediction: Enabling effective ICU antibiotic stewardship
基于因果关系建模的多重耐药菌预测模型：助力重症监护室（ICU）有效开展抗生素管理
Linna Wang, Xinyu Guo, Yimin Chen, Siying Li, ... Li Lu
Article 107767
Reviews（综述）
4.
Tissue pharmacokinetics of antifungal drugs: a review
抗真菌药物的组织药代动力学：综述
Felix Bergmann, Marlene Prager, Lena Pracher, Anselm Jorda, ... Markus Zeitlinger
Article 107743
5.
New-generation antibiotics and nonantibiotic strategies against carbapenemase-producing Enterobacterales: More focus on metallo-β-lactamase producers
新一代抗生素及非抗生素策略针对产碳青霉烯酶肠杆菌科细菌：更聚焦于产金属β-内酰胺酶菌种
Shio-Shin Jean, Chih-Cheng Lai, Hou-Tai Chang, Hui-Che Hsiao, ... Po-Ren Hsueh
Article 107750
6.
A window into resistance: The MEGA-plate as a model of evolutionary dynamics
洞见耐药性：MEGA 培养皿——一种模拟进化动态的模型
Maytham Hussein, Rafah Allobawi, James Barclay, Zhi Ying Kho, ... Tony Velkov
Article 107751
7.
Formulating and stabilising therapeutic phages: A review
治疗性噬菌体的配制与稳定化：综述
Eleni Siafakas, Hien T.T. Duong, Jonathan R. Iredell
Article 107759
Full Length Articles（长篇论著）
8.
Efficacy and safety of intracameral amphotericin B for fungal keratitis: A systematic review and meta-analysis
眼内注射两性霉素B治疗真菌性角膜炎的疗效与安全性：一项系统综述与荟萃分析
Kai-Yang Chen, Hoi-Chun Chan, Chi-Ming Chan
Article 107707
9.
Urine NGAL adds to serum creatinine in predicting cefepime clearance in critically ill children at high risk of acute kidney injury
尿中性粒细胞明胶酶相关脂质运载蛋白（NGAL）联合血清肌酐，可更有效地预测急性肾损伤高风险危重症儿童头孢吡肟的清除率
Horace Rhodes Hambrick, Ronaldo Morales Junior, Calise Curry, Michaela Collins, ... Sonya Tang Girdwood
Article 107741
10.
Integrative virtual and empirical screening to identify multi-target flavonoid quercetin-3-O-glucuronide for reducing MRSA pathogenicity
通过整合虚拟筛选与实证筛选，确定具有多靶点作用的黄酮类化合物槲皮素-3-O-葡萄糖醛酸苷可降低耐甲氧西林金黄色葡萄球菌（MRSA）的致病性
Hang Gao, Li Wang, Zeze Fu, Yun Sun, ... Yicheng Zhao
Article 107744
11.
Validation of limited sampling strategies for polymyxin B therapeutic drug monitoring in critical care
重症监护中多粘菌素B治疗药物监测有限采样策略的验证
Yury A. Surovoy, Inna A. Galvidis, Akmal I. Alimov, Sergei V. Tsarenko, Maksim A. Burkin
Article 107740
12.
Population pharmacokinetics of cefazolin and metronidazole in patients undergoing elective colorectal surgery
择期结直肠手术患者头孢唑林和甲硝唑的群体药代动力学研究
Rochelle Ryan, Scott McDonald, Steven C Wallis, Andre van Zundert, ... Jason A. Roberts
Article 107742
13.
Omeprazole is associated with voriconazole-associated hepatotoxicity: PPI-stratified analysis and a clinically actionable nomogram from an 848-patient cohort
奥美拉唑与伏立康唑相关肝毒性有关：基于848例患者队列的质子泵抑制剂分层分析及临床可操作的列线图
Yuhang Ding, Yanhong Meng, Huaijun Zhu, Jinping Zhang, Qiuhui Wu
Article 107749
14.
Treatment sequences of a phage and colistin combination trigger different evolution pathways of a multidrug-resistant Acinetobacter baumannii yielding distinct treatment outcomes
噬菌体与粘菌素（多粘菌素E）联合用药的不同治疗顺序可引发多重耐药鲍曼不动杆菌的不同进化路径，进而产生截然不同的治疗效果
Subhankar Mukhopadhyay, Xiaoxu Zhang, Kenneth K.W. To, Yannan Liu, ... Sharon S.Y. Leung
Article 107745
15.
L-Cycloserine, not d-Cycloserine, inhibits IscS-mediated iron–sulfur cluster biosynthesis in Escherichia coli
L-环丝氨酸（而非D-环丝氨酸）抑制大肠杆菌中由IscS介导的铁硫簇生物合成
Lihe Zhang, Yongjuan Li, Yuhang Bao, Jie Feng, ... Wu Wang
Article 107761
16.
cirA promoter disruption and SHV-12 production contribute to cefiderocol resistance in carbapenem-resistant Klebsiella pneumoniae
cirA 启动子破坏与SHV-12 产生导致碳青霉烯耐药肺炎克雷伯菌对头孢地尔耐药
Fang Shen, Xiaochen Liu, Tailong Lei, Jingjing Quan, ... Qiucheng Shi
Article 107756
17.
Molecular mechanisms and clonal distribution of cefiderocol-resistant blaNDM-carrying Escherichia coli: A multi-centre study in China
携带产头孢他啶/阿维巴坦耐药基因blaNDM的大肠杆菌的分子机制及克隆分布：中国多中心研究
Chengkang Tang, Siquan Shen, Renru Han, Dandan Yin, ... Fupin Hu
Article 107762
Short Communications（短讯）
18.
Present trajectories to forecasted future: A longitudinal analysis of hospital antibiotic use in China from 2013 to 2024 and projections to 2030
现状轨迹至预测未来：2013 年至 2024 年中国医院抗生素使用情况的纵向分析及至 2030 年的预测
Weibin Li, Fenqi Du, Ruowei Xiao, Weihsin Ko, ... Haishaerjiang Wushouer
Article 107764
Letters to the Editor（致编辑的信）
19.
Comment on ‘Pharmacokinetics of ampicillin, sulbactam, and combined ampicillin/sulbactam in subcutis, muscle, and plasma: A microdialysis trial in healthy volunteers’
对“氨苄西林、舒巴坦及氨苄西林/舒巴坦联合用药在皮下组织、肌肉和血浆中的药代动力学：一项在健康志愿者中进行的微透析试验”的评论
Kishankumar Mahida, Snehal Rajendra Jagtap
Article 107736
20.
Comment on: “Therapeutic drug monitoring of isavuconazole: Trends and update”
述评：“艾沙康唑治疗药物监测：趋势与最新进展”
Zhibin Xu, Shouning Zhou, Lulin Wang, Xiaohua Wang, ... Chunrong Ju
Article 107732
21.
Comprehensive analysis of 16S rRNA methyltransferases in Enterobacterales isolated from dogs and cats reveals co-resistance with broad-spectrum β-lactamases
对从猫狗体内分离出的肠杆菌目细菌中16S rRNA甲基转移酶的全面分析揭示其与广谱β-内酰胺酶共存耐药性
Fábio Parra Sellera, Yawen Yu, Yingying Zhang, Luciana Sartori, ... João Pedro Rueda Furlan
Article 107747
22.
Comment on "Effect of probiotic strain, duration, and dose on preventing ICU-acquired infection: A scoping review"
评论：“益生菌菌株、疗程和剂量对预防重症监护病房获得性感染的影响：一项范围综述”
Jiayi Yu
Article 107758
23.
Comment on “Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis”
对《肾盂肾炎及复杂性尿路感染治疗中不同类别抗生素的比较：一项系统综述与荟萃分析》一文的评论
Qiao Chen
Article 107770
International Journal of Antimicrobial Agents Volume 67, Issue 6
国际抗微生物制剂杂志 67卷 6期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/6
AI strategies to combat AMR（应对抗菌药物耐药性的人工智能策略）
1.
Surgical MAchine learning model for predicting Risk of postoperative infecTions in general elective surgery (SMART): A modelling study
用于预测普通择期手术术后感染风险的手术机器学习模型（SMART）：一项建模研究
Nehal Hassan, Robert Slight, Graham Morgan, Daniel Weiand, ... Sarah P. Slight
Article 107768
Reviews（综述）
2.
Prophylactic and therapeutic efficacy of monoclonal antibodies against avian influenza H5N1 virus
抗禽流感H5N1病毒单克隆抗体的预防和治疗功效
Antonios-Periklis Panagiotopoulos, Cleo Anastassopoulou, Kyriaki Ranellou, Ilias Mariolis, Athanasios Tsakris
Article 107784
Full Length Articles（长篇论著）
3.
Broad-host-range Kayvirus phages preferentially infect Staphylocococcus aureus cells with β-glycosylated WTA, the most common bacterial form in the human host
广泛宿主范围卡伊病毒噬菌体优先感染携带β-糖基化壁磷壁酸（WTA）的金黄色葡萄球菌细胞，此为人类宿主中最常见的细菌形式
Andrea Jurado, Carlos C. Gómez-Cambronero, Ana Rodríguez, Daniel Lopez, ... Lucía Fernández
Article 107755
4.
Characterization of KPC-176, an S171P variant derived from KPC-2, associated with ceftazidime-avibactam resistance in ST11-KL64 Klebsiella pneumoniae
KPC-176的特征分析，该变异体源自KPC-2，其S171P变异与ST11-KL64型肺炎克雷伯菌对头孢他啶-阿维巴坦的耐药性相关
Yinyin Hu, Lufei Yuan, Zhaoxin Xia, Tian Wan, ... Jilu Shen
Article 107773
5.
Development and validation of a predictive model for profiling antibiotic resistance phenotypes of Acinetobacter baumannii strains via clinical MALDI-TOF mass spectra: A multicenter study
通过临床基质辅助激光解吸电离飞行时间质谱（MALDI-TOF MS）建立并验证预测鲍曼不动杆菌菌株抗生素耐药表型的模型：一项多中心研究
Quan Yuan, Su-Ling Liu, Luan Luan, Yue-Ting Jiang, ... Liang Wang
Article 107760
6.
Access to new antibacterials in 10 Asian countries: An Asian network for surveillance of resistant pathogens study
10个亚洲国家获得新型抗菌药物的情况：一项亚洲耐药病原体监测网络研究
Young Ho Lee, Helmi bin Sulaiman, Visanu Thamlikitkul, David Chien Lye, ... Kyungmin Huh
Article 107769
7.
Human serum albumin and biological fluids reduce cefiderocol activity in carbapenem-resistant gram-negative bacteria
人血清白蛋白及生物体液会降低头孢地尔对碳青霉烯类耐药革兰氏阴性菌的活性
Azadeh Varnado, Samyar Moheb, Shayra D. Sanchez, Cecilia Rodriguez, ... Maria S. Ramirez
Article 107781
8.
Minor non-fermenting Gram-negative bacilli in Europe, 2020–2024 (MINOFEu)
2020 - 2024年欧洲非发酵型革兰氏阴性杆菌情况（MINOFEu）
Gabriele Bianco, Paulo Bastos, Konstantina Gartzonika, Eirini Christaki, ... Matteo Boattini
Article 107772
9.
Amphotericin B ameliorates obesity through modulating gut mycobiome dysbiosis and brown adipose tissue thermogenesis in high-fat diet-induced mice
两性霉素B通过调节高脂饮食诱导小鼠的肠道真菌群失调和棕色脂肪组织产热来改善肥胖
Yinghan Xiang, Zhouyi Wang, Jiaxin An, Qianrui Wei, ... Huajun Li
Article 107780
10.
Repurposing sulfamethoxazole via gold nanocluster modification for antibacterial and anti-biofilm activity against multidrug-resistant Gram-negative bacteria
通过金纳米簇修饰重新利用磺胺甲恶唑以获得针对多重耐药革兰氏阴性菌的抗菌和抗生物膜活性
Yiwen Xue, Yujing Wang, Congcong You, Yanlei Zheng, ... Tieli Zhou
Article 107757
11.
Do predictors of vancomycin trough concentration non-attainment differ for subtherapeutic and supratherapeutic levels? A 9-year stratified analysis in critically ill patients
对于万古霉素谷浓度未达标情况，亚治疗水平（浓度过低）与超治疗水平（浓度过高）的预测因素是否不同？一项针对危重症患者为期9年的分层分析
Yun Yang, Ying Zhu, Jun You, Jiali Zhang, ... Ping Wang
Article 107779
12.
Ceftazidime/avibactam-resistant carbapenem-resistant Klebsiella pneumoniae in China: A nationwide multicenter study
中国耐头孢他啶/阿维巴坦的碳青霉烯类耐药肺炎克雷伯菌：一项全国多中心研究
Rongqi Lu, Yun Wu, Ruirui Ma, Rongxiang Feng, ... Yali Liu
Article 107774
13.
Population pharmacokinetics and dosing regimen optimization of ceftazidime in plasma and cerebrospinal fluid of neonatal sepsis patients
新生儿败血症患者血浆及脑脊液中头孢他啶的群体药代动力学与给药方案优化
Zuo Wang, Yingying Xin, Ying Deng, Ting Xia, ... Yang Wang
Article 107783
14.
Global burden of antimicrobial resistance in lower respiratory infections: A systematic analysis for the Global Burden of Disease Study 2021
下呼吸道感染中抗菌药物耐药性的全球负担：2021年全球疾病负担研究的系统分析
Weidong Qin, Hao Wang, Kunpeng Lv, Sa Liu, ... Yuguo Chen
Article 107786
15.
Spontaneous mutations to delamanid and pretomanid resistance in Mycobacterium tuberculosis: SNPs confer high-level resistance
结核分枝杆菌对德拉马尼和普托马尼自发产生耐药性的突变：单核苷酸多态性（SNPs）导致高水平耐药性
Qian Zhang, Peng Xu, Xuecong Zhang, Rui Pi, ... Qian Gao
Article 107789
16.
ESBL-producing Escherichia coli bacteraemic urinary tract infections: Clinical and economic burden and antimicrobial stewardship opportunities in a retrospective cohort study
产超广谱β-内酰胺酶（ESBL）大肠埃希菌致血行性尿路感染：一项回顾性队列研究中的临床与经济负担及抗菌药物管理机遇
Silvia Gómez-Zorrilla, Grethel Rodríguez-Cabalé, Inmaculada López Montesinos, Soukaina Sara Alanti, ... Juan P. Horcajada
Article 107787
17.
Distribution of piperacillin-tazobactam into cerebrospinal, peritoneal, and pleural fluid in children aged 0–18 years
0至18岁儿童哌拉西林-他唑巴坦在脑脊液、腹水和胸腔积液中的分布情况
Jinglei Wang, Wenyu Yang, Alice Lei, Kiera Harwood, ... Amanda Gwee
Article 107793
18.
Letermovir for CMV prophylaxis after haploidentical HSCT: A prospective study of direct and indirect effects
来特莫韦用于单倍体相合造血干细胞移植后巨细胞病毒预防：一项关于直接和间接效应的前瞻性研究
Tong Cui, Chengsen Cai, Shiyuan Zhou, Yuejun Liu, ... Xiaojin Wu
Article 107790
19.
Efficacy, safety, and population pharmacokinetics of eravacycline for carbapenem-resistant organism infections in immunocompromised hosts: A multicenter prospective cohort study
依拉环素治疗免疫功能低下宿主碳青霉烯类耐药菌感染的疗效、安全性及群体药代动力学：一项多中心前瞻性队列研究
Yifu Hou, Lijuan Zhang, Hong Li, Linhong Zhong, ... Lingai Pan
Article 107795
20.
Mobile colistin resistance in New Zealand without local agricultural colistin use: Genomic insights into mcr-carrying plasmids and their global context, 1984–2024
新西兰本地未使用粘菌素农业用药却出现粘菌素耐药菌移动现象：关于携带mcr基因质粒及其1984-2024年全球背景的基因组学见解
Jenny Szeto, Rhys T. White, Hermes Perez, Allan Hardaker, ... Zuyu Yang
Article 107801
Short Communications（简讯）
21.
Early risk stratification in Staphylococcus aureus bacteraemia: External validation of the FEN-AUREUS classification in a UK cohort
金黄色葡萄球菌菌血症的早期风险分层：FEN-AUREUS分类在英国队列中的外部验证
Belén Gutiérrez-Gutiérrez, Luis Eduardo López-Cortés, Giulia Zumbo, Jesús Rodríguez-Baño, Clark D. Russell
Article 107778
22.
Global genomic surveillance of tigecycline resistance gene tet(X) in Salmonella enterica
全球范围内对肠沙门氏菌中替加环素耐药基因tet(X) 的基因组监测
Jing Wang, Wenyi Li, Jia-Qing Hou, Peng-Yun Shao, ... Qiuchun Li
Article 107794
23.
Plasma and subcutaneous interstitial fluid vancomycin and gentamicin concentrations in three patients undergoing open abdominal aortic aneurysm repair
三例接受开放性腹主动脉瘤修复术患者血浆及皮下组织间液中万古霉素和庆大霉素的浓度
Rochelle Ryan, Paul Jarrett, Melissa Lassig-Smith, Steven C. Wallis, ... Jason A. Roberts
Article 107796
Letters to the Editor（致编辑的信）
24.
Comment on “Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis”
《肾盂肾炎及复杂性尿路感染治疗中不同类别抗生素的比较：一项系统综述与荟萃分析》述评
Chandana Maji, Hariharan Srinivasan, Aishwarya Biradar, Reenoo Jauhari
Article 107771
25.
Clonal spread of NDM-1-producing Moellerella wisconsensis between cattle farm and mutton
产NDM-1的威斯康星莫勒氏菌在养牛场与羊肉之间的克隆传播
Ludan Xiao, Xingxing Zhang, Chao Yue, Zhongpeng Cai, ... Yi-Yun Liu
Article 107748
26.
In reply to the letter to editor regarding ‘Pharmacokinetics of ampicillin, sulbactam, and combined ampicillin/sulbactam in subcutis, muscle, and plasma: A microdialysis trial in healthy volunteers’
回复关于“氨苄西林、舒巴坦及氨苄西林/舒巴坦联合用药在皮下、肌肉和血浆中的药代动力学：一项健康志愿者微透析试验”的致编辑信
Anselm Jorda, Markus Zeitlinger, Valentin al Jalali
Article 107752
27.
Reply to the letter to the editor regarding ‘Acute kidney injury associated with colistin sulfate vs. polymyxin B sulfate therapy: A real-world, retrospective cohort study’
回复：关于“硫酸黏菌素与硫酸多黏菌素B治疗相关急性肾损伤：一项真实世界回顾性队列研究”的致编辑的信
Yanfang Zhang, Ziqi Ye, Saiping Jiang
Article 107763
28.
In reply to the letter to editor regarding: Effect of probiotic strain, duration, and dose on preventing ICU-acquired infection: A scoping review
回复关于《益生菌菌株、疗程及剂量对预防重症监护病房获得性感染的影响：一项范围综述》一文致编辑的来信
Aqdar Mufareh Al-Aklabi, Sara Muteb Alotaishan, Yasmin Youssuf Al-Gindan, Rabie Yousif Khattab
Article 107782
29.
Comment on “Beneficial effects of a compound probiotic in Helicobacter pylori-infected patients aged over 40 years: An open-label randomized clinical trial”
对“复合益生菌对40岁以上幽门螺杆菌感染患者的有益作用：一项开放标签随机临床试验”的评论
Palavardhan Peddapalegani, Raghav Gupta, Priyanka Bansal, Pankaj Nainwal, Hariharan Srinivasan
Article 107785
30.
Comment on ‘Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis’
对“用于治疗肾盂肾炎和复杂性尿路感染的抗生素类别比较：一项系统综述和荟萃分析”的评论
Congyao Wang, Jinwen Chen, Huizhong Yang, Mengjin Jiang
Article 107777
31.
In reply to the Letter to Editor regarding “Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis”
回复关于“治疗肾盂肾炎和复杂性尿路感染的抗生素类别比较：一项系统综述和荟萃分析”的致编辑信
Itay Zahavi, Digbijay Kunwar, Judit Olchowski, Hagar Dallasheh, Mical Paul
Article 107791
32.
In Reply to the Letter to Editor Regarding "Phage Therapy for KPC-Producing Klebsiella pneumoniae Decolonization in High-Risk Patients: The KIDNAP Study Protocol - A Prospective Feasibility and Proof of Concept Study in the Brazilian Context"
回复关于“噬菌体疗法用于高危患者产KPC肺炎克雷伯菌的根除：《KIDNAP研究方案》——巴西背景下的一项前瞻性可行性及概念验证研究”的致编辑信
Iris Najjar, Larissa Simão Gandolpho, Jôiciglecia Pereira dos Santos, Camila de Paula Siqueira, ... Ana C Gales
Article 107788
International Journal of Antimicrobial Agents Volume 67, Issue 7
国际抗微生物制剂杂志 67卷 7期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/7
Full Length Articles（长篇论著）
1.
Targeting the human protein disulfide isomerase A3 as a broad-spectrum antiviral approach against human respiratory viruses
以人蛋白二硫键异构酶A3为靶点，开发针对人类呼吸道病毒的广谱抗病毒方法
Giulia Sibille, Arianna Maggiora, Giorgia Cimato, Anna Luganini, Giorgio Gribaudo
Article 107802
2.
Comparative outcomes of daptomycin and linezolid in vancomycin-resistant enterococcal intra-abdominal infections with bacteraemia
达托霉素与利奈唑胺治疗耐万古霉素肠球菌所致伴菌血症的腹腔内感染的疗效比较
Tsung-Yu Tsai, Yu-Chung Chuang, Jia-Ling Yang, Chi-Ying Lin, ... Shan-Chwen Chang
Article 107792
Letters to the Editor（致编辑的信）
3.
In reply to the letter to the editor regarding “Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis”
回复致编辑关于“治疗肾盂肾炎和复杂性尿路感染的抗生素类别比较：一项系统综述和荟萃分析”的来信
Itay Zahavi, Digbijay Kunwar, Judit Olchowski, Hagar Dallasheh, Mical Paul
Article 107800
4.
Comment on “Enhancing meropenem therapy in critical care: A retrospective study of PK/PD target attainment and therapeutic drug monitoring”
对“加强重症监护病房美罗培南治疗：一项关于药代动力学/药效学目标达成情况和治疗药物监测的回顾性研究”的评论
Xuefeng Yu
Article 107804
2026-04-24
International Journal of Antimicrobial Agents Volume 67, Issue 5
国际抗微生物制剂杂志 67卷5期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/5
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与资讯页）
1.
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page
国际抗菌化疗学会（ISAC）新闻与资讯页
Article 107803
Global Landscape of Phage Therapy（噬菌体疗法的全球概况）
2.
Assessing carbonylation in Pseudomonas aeruginosa clinical isolates infected by bacteriophages using flow cytometry
利用流式细胞术评估受噬菌体感染的铜绿假单胞菌临床分离株中的羰基化情况
Jia Hao Yeo, Shuhua Thong, Shimin Jasmine Chung, Andrea Lay-Hoon Kwa
Article 107739
AI strategies to combat AMR（应对抗菌药物耐药性的人工智能策略）
3.
Causality-informed models for multidrug-resistant organism prediction: Enabling effective ICU antibiotic stewardship
基于因果关系建模的多重耐药菌预测模型：助力重症监护室（ICU）有效开展抗生素管理
Linna Wang, Xinyu Guo, Yimin Chen, Siying Li, ... Li Lu
Article 107767
Reviews（综述）
4.
Tissue pharmacokinetics of antifungal drugs: a review
抗真菌药物的组织药代动力学：综述
Felix Bergmann, Marlene Prager, Lena Pracher, Anselm Jorda, ... Markus Zeitlinger
Article 107743
5.
New-generation antibiotics and nonantibiotic strategies against carbapenemase-producing Enterobacterales: More focus on metallo-β-lactamase producers
新一代抗生素及非抗生素策略针对产碳青霉烯酶肠杆菌科细菌：更聚焦于产金属β-内酰胺酶菌种
Shio-Shin Jean, Chih-Cheng Lai, Hou-Tai Chang, Hui-Che Hsiao, ... Po-Ren Hsueh
Article 107750
6.
A window into resistance: The MEGA-plate as a model of evolutionary dynamics
洞见耐药性：MEGA 培养皿——一种模拟进化动态的模型
Maytham Hussein, Rafah Allobawi, James Barclay, Zhi Ying Kho, ... Tony Velkov
Article 107751
7.
Formulating and stabilising therapeutic phages: A review
治疗性噬菌体的配制与稳定化：综述
Eleni Siafakas, Hien T.T. Duong, Jonathan R. Iredell
Article 107759
Full Length Articles（长篇论著）
8.
Efficacy and safety of intracameral amphotericin B for fungal keratitis: A systematic review and meta-analysis
眼内注射两性霉素B治疗真菌性角膜炎的疗效与安全性：一项系统综述与荟萃分析
Kai-Yang Chen, Hoi-Chun Chan, Chi-Ming Chan
Article 107707
9.
Urine NGAL adds to serum creatinine in predicting cefepime clearance in critically ill children at high risk of acute kidney injury
尿中性粒细胞明胶酶相关脂质运载蛋白（NGAL）联合血清肌酐，可更有效地预测急性肾损伤高风险危重症儿童头孢吡肟的清除率
Horace Rhodes Hambrick, Ronaldo Morales Junior, Calise Curry, Michaela Collins, ... Sonya Tang Girdwood
Article 107741
10.
Integrative virtual and empirical screening to identify multi-target flavonoid quercetin-3-O-glucuronide for reducing MRSA pathogenicity
通过整合虚拟筛选与实证筛选，确定具有多靶点作用的黄酮类化合物槲皮素-3-O-葡萄糖醛酸苷可降低耐甲氧西林金黄色葡萄球菌（MRSA）的致病性
Hang Gao, Li Wang, Zeze Fu, Yun Sun, ... Yicheng Zhao
Article 107744
11.
Validation of limited sampling strategies for polymyxin B therapeutic drug monitoring in critical care
重症监护中多粘菌素B治疗药物监测有限采样策略的验证
Yury A. Surovoy, Inna A. Galvidis, Akmal I. Alimov, Sergei V. Tsarenko, Maksim A. Burkin
Article 107740
12.
Population pharmacokinetics of cefazolin and metronidazole in patients undergoing elective colorectal surgery
择期结直肠手术患者头孢唑林和甲硝唑的群体药代动力学研究
Rochelle Ryan, Scott McDonald, Steven C Wallis, Andre van Zundert, ... Jason A. Roberts
Article 107742
13.
Omeprazole is associated with voriconazole-associated hepatotoxicity: PPI-stratified analysis and a clinically actionable nomogram from an 848-patient cohort
奥美拉唑与伏立康唑相关肝毒性有关：基于848例患者队列的质子泵抑制剂分层分析及临床可操作的列线图
Yuhang Ding, Yanhong Meng, Huaijun Zhu, Jinping Zhang, Qiuhui Wu
Article 107749
14.
Treatment sequences of a phage and colistin combination trigger different evolution pathways of a multidrug-resistant Acinetobacter baumannii yielding distinct treatment outcomes
噬菌体与粘菌素（多粘菌素E）联合用药的不同治疗顺序可引发多重耐药鲍曼不动杆菌的不同进化路径，进而产生截然不同的治疗效果
Subhankar Mukhopadhyay, Xiaoxu Zhang, Kenneth K.W. To, Yannan Liu, ... Sharon S.Y. Leung
Article 107745
15.
L-Cycloserine, not d-Cycloserine, inhibits IscS-mediated iron–sulfur cluster biosynthesis in Escherichia coli
L-环丝氨酸（而非D-环丝氨酸）抑制大肠杆菌中由IscS介导的铁硫簇生物合成
Lihe Zhang, Yongjuan Li, Yuhang Bao, Jie Feng, ... Wu Wang
Article 107761
16.
cirA promoter disruption and SHV-12 production contribute to cefiderocol resistance in carbapenem-resistant Klebsiella pneumoniae
cirA 启动子破坏与SHV-12 产生导致碳青霉烯耐药肺炎克雷伯菌对头孢地尔耐药
Fang Shen, Xiaochen Liu, Tailong Lei, Jingjing Quan, ... Qiucheng Shi
Article 107756
17.
Molecular mechanisms and clonal distribution of cefiderocol-resistant blaNDM-carrying Escherichia coli: A multi-centre study in China
携带产头孢他啶/阿维巴坦耐药基因blaNDM的大肠杆菌的分子机制及克隆分布：中国多中心研究
Chengkang Tang, Siquan Shen, Renru Han, Dandan Yin, ... Fupin Hu
Article 107762
Short Communications（短讯）
18.
Present trajectories to forecasted future: A longitudinal analysis of hospital antibiotic use in China from 2013 to 2024 and projections to 2030
现状轨迹至预测未来：2013 年至 2024 年中国医院抗生素使用情况的纵向分析及至 2030 年的预测
Weibin Li, Fenqi Du, Ruowei Xiao, Weihsin Ko, ... Haishaerjiang Wushouer
Article 107764
Letters to the Editor（致编辑的信）
19.
Comment on ‘Pharmacokinetics of ampicillin, sulbactam, and combined ampicillin/sulbactam in subcutis, muscle, and plasma: A microdialysis trial in healthy volunteers’
对“氨苄西林、舒巴坦及氨苄西林/舒巴坦联合用药在皮下组织、肌肉和血浆中的药代动力学：一项在健康志愿者中进行的微透析试验”的评论
Kishankumar Mahida, Snehal Rajendra Jagtap
Article 107736
20.
Comment on: “Therapeutic drug monitoring of isavuconazole: Trends and update”
述评：“艾沙康唑治疗药物监测：趋势与最新进展”
Zhibin Xu, Shouning Zhou, Lulin Wang, Xiaohua Wang, ... Chunrong Ju
Article 107732
21.
Comprehensive analysis of 16S rRNA methyltransferases in Enterobacterales isolated from dogs and cats reveals co-resistance with broad-spectrum β-lactamases
对从猫狗体内分离出的肠杆菌目细菌中16S rRNA甲基转移酶的全面分析揭示其与广谱β-内酰胺酶共存耐药性
Fábio Parra Sellera, Yawen Yu, Yingying Zhang, Luciana Sartori, ... João Pedro Rueda Furlan
Article 107747
22.
Comment on "Effect of probiotic strain, duration, and dose on preventing ICU-acquired infection: A scoping review"
评论：“益生菌菌株、疗程和剂量对预防重症监护病房获得性感染的影响：一项范围综述”
Jiayi Yu
Article 107758
23.
Comment on “Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis”
对《肾盂肾炎及复杂性尿路感染治疗中不同类别抗生素的比较：一项系统综述与荟萃分析》一文的评论
Qiao Chen
Article 107770
International Journal of Antimicrobial Agents Volume 67, Issue 6
国际抗微生物制剂杂志 67卷 6期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/6
AI strategies to combat AMR（应对抗菌药物耐药性的人工智能策略）
1.
Surgical MAchine learning model for predicting Risk of postoperative infecTions in general elective surgery (SMART): A modelling study
用于预测普通择期手术术后感染风险的手术机器学习模型（SMART）：一项建模研究
Nehal Hassan, Robert Slight, Graham Morgan, Daniel Weiand, ... Sarah P. Slight
Article 107768
Reviews（综述）
2.
Prophylactic and therapeutic efficacy of monoclonal antibodies against avian influenza H5N1 virus
抗禽流感H5N1病毒单克隆抗体的预防和治疗功效
Antonios-Periklis Panagiotopoulos, Cleo Anastassopoulou, Kyriaki Ranellou, Ilias Mariolis, Athanasios Tsakris
Article 107784
Full Length Articles（长篇论著）
3.
Broad-host-range Kayvirus phages preferentially infect Staphylocococcus aureus cells with β-glycosylated WTA, the most common bacterial form in the human host
广泛宿主范围卡伊病毒噬菌体优先感染携带β-糖基化壁磷壁酸（WTA）的金黄色葡萄球菌细胞，此为人类宿主中最常见的细菌形式
Andrea Jurado, Carlos C. Gómez-Cambronero, Ana Rodríguez, Daniel Lopez, ... Lucía Fernández
Article 107755
4.
Characterization of KPC-176, an S171P variant derived from KPC-2, associated with ceftazidime-avibactam resistance in ST11-KL64 Klebsiella pneumoniae
KPC-176的特征分析，该变异体源自KPC-2，其S171P变异与ST11-KL64型肺炎克雷伯菌对头孢他啶-阿维巴坦的耐药性相关
Yinyin Hu, Lufei Yuan, Zhaoxin Xia, Tian Wan, ... Jilu Shen
Article 107773
5.
Development and validation of a predictive model for profiling antibiotic resistance phenotypes of Acinetobacter baumannii strains via clinical MALDI-TOF mass spectra: A multicenter study
通过临床基质辅助激光解吸电离飞行时间质谱（MALDI-TOF MS）建立并验证预测鲍曼不动杆菌菌株抗生素耐药表型的模型：一项多中心研究
Quan Yuan, Su-Ling Liu, Luan Luan, Yue-Ting Jiang, ... Liang Wang
Article 107760
6.
Access to new antibacterials in 10 Asian countries: An Asian network for surveillance of resistant pathogens study
10个亚洲国家获得新型抗菌药物的情况：一项亚洲耐药病原体监测网络研究
Young Ho Lee, Helmi bin Sulaiman, Visanu Thamlikitkul, David Chien Lye, ... Kyungmin Huh
Article 107769
7.
Human serum albumin and biological fluids reduce cefiderocol activity in carbapenem-resistant gram-negative bacteria
人血清白蛋白及生物体液会降低头孢地尔对碳青霉烯类耐药革兰氏阴性菌的活性
Azadeh Varnado, Samyar Moheb, Shayra D. Sanchez, Cecilia Rodriguez, ... Maria S. Ramirez
Article 107781
8.
Minor non-fermenting Gram-negative bacilli in Europe, 2020–2024 (MINOFEu)
2020 - 2024年欧洲非发酵型革兰氏阴性杆菌情况（MINOFEu）
Gabriele Bianco, Paulo Bastos, Konstantina Gartzonika, Eirini Christaki, ... Matteo Boattini
Article 107772
9.
Amphotericin B ameliorates obesity through modulating gut mycobiome dysbiosis and brown adipose tissue thermogenesis in high-fat diet-induced mice
两性霉素B通过调节高脂饮食诱导小鼠的肠道真菌群失调和棕色脂肪组织产热来改善肥胖
Yinghan Xiang, Zhouyi Wang, Jiaxin An, Qianrui Wei, ... Huajun Li
Article 107780
10.
Repurposing sulfamethoxazole via gold nanocluster modification for antibacterial and anti-biofilm activity against multidrug-resistant Gram-negative bacteria
通过金纳米簇修饰重新利用磺胺甲恶唑以获得针对多重耐药革兰氏阴性菌的抗菌和抗生物膜活性
Yiwen Xue, Yujing Wang, Congcong You, Yanlei Zheng, ... Tieli Zhou
Article 107757
11.
Do predictors of vancomycin trough concentration non-attainment differ for subtherapeutic and supratherapeutic levels? A 9-year stratified analysis in critically ill patients
对于万古霉素谷浓度未达标情况，亚治疗水平（浓度过低）与超治疗水平（浓度过高）的预测因素是否不同？一项针对危重症患者为期9年的分层分析
Yun Yang, Ying Zhu, Jun You, Jiali Zhang, ... Ping Wang
Article 107779
12.
Ceftazidime/avibactam-resistant carbapenem-resistant Klebsiella pneumoniae in China: A nationwide multicenter study
中国耐头孢他啶/阿维巴坦的碳青霉烯类耐药肺炎克雷伯菌：一项全国多中心研究
Rongqi Lu, Yun Wu, Ruirui Ma, Rongxiang Feng, ... Yali Liu
Article 107774
13.
Population pharmacokinetics and dosing regimen optimization of ceftazidime in plasma and cerebrospinal fluid of neonatal sepsis patients
新生儿败血症患者血浆及脑脊液中头孢他啶的群体药代动力学与给药方案优化
Zuo Wang, Yingying Xin, Ying Deng, Ting Xia, ... Yang Wang
Article 107783
14.
Global burden of antimicrobial resistance in lower respiratory infections: A systematic analysis for the Global Burden of Disease Study 2021
下呼吸道感染中抗菌药物耐药性的全球负担：2021年全球疾病负担研究的系统分析
Weidong Qin, Hao Wang, Kunpeng Lv, Sa Liu, ... Yuguo Chen
Article 107786
15.
Spontaneous mutations to delamanid and pretomanid resistance in Mycobacterium tuberculosis: SNPs confer high-level resistance
结核分枝杆菌对德拉马尼和普托马尼自发产生耐药性的突变：单核苷酸多态性（SNPs）导致高水平耐药性
Qian Zhang, Peng Xu, Xuecong Zhang, Rui Pi, ... Qian Gao
Article 107789
16.
ESBL-producing Escherichia coli bacteraemic urinary tract infections: Clinical and economic burden and antimicrobial stewardship opportunities in a retrospective cohort study
产超广谱β-内酰胺酶（ESBL）大肠埃希菌致血行性尿路感染：一项回顾性队列研究中的临床与经济负担及抗菌药物管理机遇
Silvia Gómez-Zorrilla, Grethel Rodríguez-Cabalé, Inmaculada López Montesinos, Soukaina Sara Alanti, ... Juan P. Horcajada
Article 107787
17.
Distribution of piperacillin-tazobactam into cerebrospinal, peritoneal, and pleural fluid in children aged 0–18 years
0至18岁儿童哌拉西林-他唑巴坦在脑脊液、腹水和胸腔积液中的分布情况
Jinglei Wang, Wenyu Yang, Alice Lei, Kiera Harwood, ... Amanda Gwee
Article 107793
18.
Letermovir for CMV prophylaxis after haploidentical HSCT: A prospective study of direct and indirect effects
来特莫韦用于单倍体相合造血干细胞移植后巨细胞病毒预防：一项关于直接和间接效应的前瞻性研究
Tong Cui, Chengsen Cai, Shiyuan Zhou, Yuejun Liu, ... Xiaojin Wu
Article 107790
19.
Efficacy, safety, and population pharmacokinetics of eravacycline for carbapenem-resistant organism infections in immunocompromised hosts: A multicenter prospective cohort study
依拉环素治疗免疫功能低下宿主碳青霉烯类耐药菌感染的疗效、安全性及群体药代动力学：一项多中心前瞻性队列研究
Yifu Hou, Lijuan Zhang, Hong Li, Linhong Zhong, ... Lingai Pan
Article 107795
20.
Mobile colistin resistance in New Zealand without local agricultural colistin use: Genomic insights into mcr-carrying plasmids and their global context, 1984–2024
新西兰本地未使用粘菌素农业用药却出现粘菌素耐药菌移动现象：关于携带mcr基因质粒及其1984-2024年全球背景的基因组学见解
Jenny Szeto, Rhys T. White, Hermes Perez, Allan Hardaker, ... Zuyu Yang
Article 107801
Short Communications（简讯）
21.
Early risk stratification in Staphylococcus aureus bacteraemia: External validation of the FEN-AUREUS classification in a UK cohort
金黄色葡萄球菌菌血症的早期风险分层：FEN-AUREUS分类在英国队列中的外部验证
Belén Gutiérrez-Gutiérrez, Luis Eduardo López-Cortés, Giulia Zumbo, Jesús Rodríguez-Baño, Clark D. Russell
Article 107778
22.
Global genomic surveillance of tigecycline resistance gene tet(X) in Salmonella enterica
全球范围内对肠沙门氏菌中替加环素耐药基因tet(X) 的基因组监测
Jing Wang, Wenyi Li, Jia-Qing Hou, Peng-Yun Shao, ... Qiuchun Li
Article 107794
23.
Plasma and subcutaneous interstitial fluid vancomycin and gentamicin concentrations in three patients undergoing open abdominal aortic aneurysm repair
三例接受开放性腹主动脉瘤修复术患者血浆及皮下组织间液中万古霉素和庆大霉素的浓度
Rochelle Ryan, Paul Jarrett, Melissa Lassig-Smith, Steven C. Wallis, ... Jason A. Roberts
Article 107796
Letters to the Editor（致编辑的信）
24.
Comment on “Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis”
《肾盂肾炎及复杂性尿路感染治疗中不同类别抗生素的比较：一项系统综述与荟萃分析》述评
Chandana Maji, Hariharan Srinivasan, Aishwarya Biradar, Reenoo Jauhari
Article 107771
25.
Clonal spread of NDM-1-producing Moellerella wisconsensis between cattle farm and mutton
产NDM-1的威斯康星莫勒氏菌在养牛场与羊肉之间的克隆传播
Ludan Xiao, Xingxing Zhang, Chao Yue, Zhongpeng Cai, ... Yi-Yun Liu
Article 107748
26.
In reply to the letter to editor regarding ‘Pharmacokinetics of ampicillin, sulbactam, and combined ampicillin/sulbactam in subcutis, muscle, and plasma: A microdialysis trial in healthy volunteers’
回复关于“氨苄西林、舒巴坦及氨苄西林/舒巴坦联合用药在皮下、肌肉和血浆中的药代动力学：一项健康志愿者微透析试验”的致编辑信
Anselm Jorda, Markus Zeitlinger, Valentin al Jalali
Article 107752
27.
Reply to the letter to the editor regarding ‘Acute kidney injury associated with colistin sulfate vs. polymyxin B sulfate therapy: A real-world, retrospective cohort study’
回复：关于“硫酸黏菌素与硫酸多黏菌素B治疗相关急性肾损伤：一项真实世界回顾性队列研究”的致编辑的信
Yanfang Zhang, Ziqi Ye, Saiping Jiang
Article 107763
28.
In reply to the letter to editor regarding: Effect of probiotic strain, duration, and dose on preventing ICU-acquired infection: A scoping review
回复关于《益生菌菌株、疗程及剂量对预防重症监护病房获得性感染的影响：一项范围综述》一文致编辑的来信
Aqdar Mufareh Al-Aklabi, Sara Muteb Alotaishan, Yasmin Youssuf Al-Gindan, Rabie Yousif Khattab
Article 107782
29.
Comment on “Beneficial effects of a compound probiotic in Helicobacter pylori-infected patients aged over 40 years: An open-label randomized clinical trial”
对“复合益生菌对40岁以上幽门螺杆菌感染患者的有益作用：一项开放标签随机临床试验”的评论
Palavardhan Peddapalegani, Raghav Gupta, Priyanka Bansal, Pankaj Nainwal, Hariharan Srinivasan
Article 107785
30.
Comment on ‘Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis’
对“用于治疗肾盂肾炎和复杂性尿路感染的抗生素类别比较：一项系统综述和荟萃分析”的评论
Congyao Wang, Jinwen Chen, Huizhong Yang, Mengjin Jiang
Article 107777
31.
In reply to the Letter to Editor regarding “Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis”
回复关于“治疗肾盂肾炎和复杂性尿路感染的抗生素类别比较：一项系统综述和荟萃分析”的致编辑信
Itay Zahavi, Digbijay Kunwar, Judit Olchowski, Hagar Dallasheh, Mical Paul
Article 107791
32.
In Reply to the Letter to Editor Regarding "Phage Therapy for KPC-Producing Klebsiella pneumoniae Decolonization in High-Risk Patients: The KIDNAP Study Protocol - A Prospective Feasibility and Proof of Concept Study in the Brazilian Context"
回复关于“噬菌体疗法用于高危患者产KPC肺炎克雷伯菌的根除：《KIDNAP研究方案》——巴西背景下的一项前瞻性可行性及概念验证研究”的致编辑信
Iris Najjar, Larissa Simão Gandolpho, Jôiciglecia Pereira dos Santos, Camila de Paula Siqueira, ... Ana C Gales
Article 107788
International Journal of Antimicrobial Agents Volume 67, Issue 7
国际抗微生物制剂杂志 67卷 7期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/7
Full Length Articles（长篇论著）
1
Targeting the human protein disulfide isomerase A3 as a broad-spectrum antiviral approach against human respiratory viruses
以人蛋白二硫键异构酶A3为靶点，开发针对人类呼吸道病毒的广谱抗病毒方法
Giulia Sibille, Arianna Maggiora, Giorgia Cimato, Anna Luganini, Giorgio Gribaudo
Article 107802
100 项与 德拉马尼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 结核 | 中国 | 2018-02-17 | |
| 肺结核 | 日本 | 2014-07-04 | |
| 耐多药结核病 | 欧盟 | 2014-04-27 | |
| 耐多药结核病 | 冰岛 | 2014-04-27 | |
| 耐多药结核病 | 列支敦士登 | 2014-04-27 | |
| 耐多药结核病 | 挪威 | 2014-04-27 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 多重耐药性肺结核 | 临床3期 | 爱沙尼亚 | 2011-09-02 | |
| 多重耐药性肺结核 | 临床3期 | 拉脱维亚 | 2011-09-02 | |
| 多重耐药性肺结核 | 临床3期 | 立陶宛 | 2011-09-02 | |
| 多重耐药性肺结核 | 临床3期 | 摩尔多瓦 | 2011-09-02 | |
| 多重耐药性肺结核 | 临床3期 | 秘鲁 | 2011-09-02 | |
| 多重耐药性肺结核 | 临床3期 | 菲律宾 | 2011-09-02 | |
| 多重耐药性肺结核 | 临床3期 | 南非 | 2011-09-02 | |
| HIV感染 | 临床2期 | 印度 | 2018-01-30 | |
| HIV感染 | 临床2期 | 南非 | 2018-01-30 | |
| HIV感染 | 临床2期 | 坦桑尼亚 | 2018-01-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床2期 | 138 | 鹹積繭鬱齋築膚襯顧廠(憲顧鏇醖製壓壓襯醖鬱) = 繭醖膚繭願糧遞構廠壓 鏇鏇膚製獵製製淵壓築 (窪繭選積餘齋顧鑰糧醖, 窪顧蓋鏇憲艱膚廠顧鬱 ~ 鹽選窪遞憲廠鹹鏇遞壓) 更多 | - | 2026-05-01 | |||
鹹積繭鬱齋築膚襯顧廠(憲顧鏇醖製壓壓襯醖鬱) = 襯顧鑰選蓋壓鹽觸遞餘 鏇鏇膚製獵製製淵壓築 (窪繭選積餘齋顧鑰糧醖, 選憲膚窪蓋襯顧願遞範 ~ 餘蓋鑰齋構餘鏇窪簾積) 更多 | |||||||
临床4期 | 29 | 築鹽鑰簾遞壓蓋鬱醖廠(艱壓繭壓製簾鬱窪網觸) = 遞網鬱選蓋簾夢構顧繭 網膚築蓋遞窪艱選鏇願 (壓選鬱築鏇鑰選製製簾 ) 更多 | 积极 | 2025-12-19 | |||
临床2期 | 肺结核 一线 | 75 | 願範夢淵積繭衊鏇鹽廠(憲獵醖蓋廠積餘夢鏇衊) = grade 4 adverse event in the Sutezolid 800 mg twice daily group 繭壓製網醖夢簾餘網憲 (淵襯觸窪簾壓簾繭網構 ) 更多 | 积极 | 2025-11-01 | ||
Sutezolid 600 mg twice daily | |||||||
临床4期 | 33 | Delamanid 100 mg + optimized background regimen (OBR) | 淵蓋襯廠壓選簾齋鬱夢(築廠網壓艱醖醖夢選構) = 窪顧願醖廠艱積餘糧製 製構願壓淵襯鏇獵蓋繭 (廠構構窪窪齋簾壓壓壓 ) 更多 | 积极 | 2025-09-29 | ||
N/A | - | 積範築鹹鹽淵構餘鑰鹹(廠夢網鹽艱憲鹹簾夢蓋) = 蓋獵窪餘膚製窪簾選鹹 蓋遞憲製餘範憲製窪醖 (築壓齋蓋糧蓋鏇糧鑰積 ) | 积极 | 2025-05-16 | |||
積範築鹹鹽淵構餘鑰鹹(廠夢網鹽艱憲鹹簾夢蓋) = 膚淵鑰構製範窪獵壓獵 蓋遞憲製餘範憲製窪醖 (築壓齋蓋糧蓋鏇糧鑰積 ) | |||||||
临床2期 | 214 | Locally-used WHO-approved MDR-TB regimen in Korea (Control Arm) | 觸構廠淵選憲築獵觸襯 = 壓鹹艱廠蓋齋築膚簾齋 壓築壓鑰餘製衊鹹糧蓋 (簾餘艱齋窪廠觸遞簾鏇, 壓齋鏇膚鬱醖繭廠鬱鬱 ~ 顧製鏇淵糧艱遞範顧築) 更多 | - | 2025-01-03 | ||
(Experimental Arm) | 觸構廠淵選憲築獵觸襯 = 鹹膚艱觸觸襯醖鹽憲積 壓築壓鑰餘製衊鹹糧蓋 (簾餘艱齋窪廠觸遞簾鏇, 糧鹹窪艱壓衊襯醖艱廠 ~ 鏇膚簾膚淵壓鑰襯構廠) 更多 | ||||||
N/A | - | 58 | (24-36 weeks) | 鏇鑰繭餘糧衊築齋衊鹹(獵遞範淵淵積鏇願觸願) = 簾蓋憲憲築觸壓艱憲艱 艱選艱淵鏇蓋簾網繭憲 (襯壓糧醖蓋遞願壓蓋構 ) 更多 | 积极 | 2024-09-07 | |
18-20 months WHO-recommended regimen | 鏇鑰繭餘糧衊築齋衊鹹(獵遞範淵淵積鏇願觸願) = 壓網選艱餘醖餘鑰壓窪 艱選艱淵鏇蓋簾網繭憲 (襯壓糧醖蓋遞願壓蓋構 ) 更多 | ||||||
临床3期 | 324 | 淵齋蓋廠鹽膚繭壓網繭(壓襯選選鏇獵蓋窪顧艱) = 窪繭鹹網淵網願齋糧蓋 憲築鬱鬱衊築餘願繭簾 (艱鑰鹹願艱壓繭簾鹽觸 ) | 积极 | 2023-11-30 | |||
Contemporaneous WHO standard of care for pre-XDR TB | 淵齋蓋廠鹽膚繭壓網繭(壓襯選選鏇獵蓋窪顧艱) = 願顧鏇襯選構願憲襯鹹 憲築鬱鬱衊築餘願繭簾 (艱鑰鹹願艱壓繭簾鹽觸 ) | ||||||
N/A | - | 250 | 鹹衊醖鹹醖範廠築網齋(選製選蓋憲鹽築壓窪選) = 獵鬱膚繭顧糧鑰蓋製壓 襯鬱窪膚簾遞鏇壓範窪 (糧齋淵積餘鹹夢鬱壓鬱, 1.4 ~ 2.6) | 积极 | 2023-09-09 | ||
临床1/2期 | 37 | 範積齋獵繭網窪築簾繭(選觸窪夢襯齋鏇製獵鹽) = 醖艱齋醖齋鬱構齋顧觸 廠積襯遞構築遞膚壓觸 (簾蓋積積獵鹽積廠範簾 ) 更多 | 积极 | 2022-04-11 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用